Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

← catalyst calendar

NCT07794774 · readout in 904 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
197estimated
Sites
6
Country
Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-31

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-09-28estimatedWhen the study began enrolling
Primary completion2029-02-21estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-02-21estimatedThe whole study's end, after follow-up
First posted2026-08-31actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-31actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Obesity

Interventions

  • Drug: Berobenatide — also filed as MET097, PF-08653944
  • Other: Placebo

Primary outcome

what the primary-completion date above is the date OF
Percent change from baseline in body weight
measured Baseline, Week 72

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed